hVIVO Faces Contract Cancellations Amid Industry Volatility but Remains Optimistic

The latest update is out from Open Orphan Plc ( (GB:HVO) ).

hVIVO plc announced the cancellation and postponement of significant human challenge trial contracts, attributed to uncertainties in the pharmaceutical industry and a depressed biotech financing market. Despite these setbacks, the company maintains a strong sales pipeline with high-value opportunities and expects further contract wins in FY25. The integration of CRS Mannheim and Kiel, along with Cryostore, is progressing well, and hVIVO remains financially robust with a strong cash position, aiming to diversify its revenue streams and expand its CRO services.

The most recent analyst rating on (GB:HVO) stock is a Buy with a £35.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.

Spark’s Take on GB:HVO Stock

According to Spark, TipRanks’ AI Analyst, GB:HVO is a Outperform.

The stock is supported by strong financial performance and strategic corporate actions that enhance growth prospects. While technical indicators show moderate momentum, valuation metrics are favorable. Positive corporate events further bolster the stock’s outlook, although governance concerns are noted.

To see Spark’s full report on GB:HVO stock, click here.

More about Open Orphan Plc

hVIVO plc is a full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The company provides end-to-end clinical development services to a diverse client base, including seven of the world’s ten largest biopharma companies. Specializing in human challenge trials across infectious and respiratory indications, hVIVO operates the largest quarantine facility in London. It also offers virology and immunology laboratory services under the hLAB brand and early-phase clinical trial services through its German subsidiary, CRS. Additionally, Venn Life Sciences, another subsidiary, provides early drug development consulting and biometry services.

Average Trading Volume: 1,499,423

Technical Sentiment Signal: Sell

Current Market Cap: £109.9M

For an in-depth examination of HVO stock, go to TipRanks’ Stock Analysis page.